Jiuzhou Pharmaceutical(SH:603456) Shang Hai Zheng Quan Bao·2025-08-05 17:55Core Viewpoint - The company, Zhejiang Jiuzhou Pharmaceutical Co., Ltd., has announced its 2025 semi-annual report, highlighting its financial performance, profit distribution plan, and the use of raised funds for project investments [1][4][6]. Company Overview - Jiuzhou Pharmaceutical is recognized as a leading CDMO (Contract Development and Manufacturing Organization) in the pharmaceutical industry, focusing on innovative drug solutions and maintaining a commitment to quality and customer service [61]. - The company has achieved significant recognition, including being listed among the top 20 CDMO companies in China and receiving multiple awards for corporate social responsibility [61]. Financial Data - For the first half of 2025, the company reported a revenue of 2.871 billion yuan and a net profit attributable to shareholders of 526 million yuan [61]. - The company plans to distribute a cash dividend of 2.00 yuan per 10 shares, totaling approximately 176.34 million yuan, which represents 52.93% of the net profit for the period [39][64]. Profit Distribution Plan - The profit distribution plan for the first half of 2025 includes a cash dividend of 2.00 yuan per 10 shares, with the total cash dividend amounting to 176,342,005.60 yuan [39][64]. - The distribution will be based on the total share capital as of the dividend record date, excluding shares held in the repurchase account [39][41]. Fundraising and Investment - The company has raised a total of approximately 2.5 billion yuan through a non-public offering of shares, with a net amount of about 2.49 billion yuan after deducting issuance costs [16][45]. - A portion of the raised funds, amounting to 200 million yuan, will be used to increase capital for the "Jiuzhou Pharmaceutical (Taizhou) Co., Ltd. Innovative Drug CDMO Production Base Construction Project" [10][14][21]. Management of Raised Funds - The company has established a specialized account for managing the raised funds, ensuring compliance with regulatory requirements and protecting investor interests [46][49]. - The management of the raised funds is governed by a set of internal regulations to enhance efficiency and effectiveness in fund utilization [46][49]. Strategic Initiatives - The company is committed to enhancing its research and development capabilities, focusing on innovative technologies in green pharmaceuticals [68]. - Jiuzhou Pharmaceutical aims to improve its market position and competitiveness through strategic partnerships and expanding its CDMO business [61].